Merger momentum & margin accretion on deck — first full quarter post-JB integration

Torrent Pharma's Q2 FY27 print will be the market's first real-time read on the JB Chemicals amalgamation — which closed Jul 8, 2026, with a retroactive appointment date of Jan 21. While Q1 captured a partial quarter of integration, Q2 is the first clean, full-quarter comparison of the merged entity. The Street's focus: does revenue scale materialize, can management sustain EBITDA margins into the mid-to-high 24% range, and what's the timing on synergy capture?

A strong print would show organic growth in Torrent's domestic chronic and specialty segments intact, JB's legacy revenue flowing through with no material churn, and EBITDA margins holding or expanding into the 24–26% zone. A weak print would flag customer losses post-acquisition, margin pressure from integration costs running longer than guided, or sluggish Brazil uptake.

Full-year FY27 consensus (29 analysts) pins revenue at ₹130.6 Cr and statutory EPS growth at 15% to ₹72.69. The merger is baked into these numbers as a synergy engine. Q2 will test whether the 3-month integration window (post-closure) has yielded the operational glue the deal model promised — cross-selling, duplicate-function elimination, CDMO capacity scaling. Management cited the deal as long-term earnings accretion; this quarter should show visible momentum on that claim, especially in the chronic and ophthalmo segments where JB adds breadth.

1. Merger revenue contribution & churn rate: How much of JB's legacy ₹~1,000 Cr+ annual revenue flows through Q2, and any customer attrition post-close? 2. EBITDA margin & one-time costs: Does margin expand to 24–26% zone, or are integration costs (restructuring, redundancy removal) weighing heavier than expected? 3. Guidance reiteration: Management should reaffirm FY27 consensus or update it; any downside surprise on synergy timing could spook the Street.